Table 2.

Some GPCRs in the specific types of psychiatric disorders with the function, polymorphisms, and drugs targeting receptors.

Some GPCRs in psychiatric disorders	Normal function	Polymorphism/change in expression	Drugs targeting receptors
5HT1A receptors	Evidence that continuous antidepressant treatment results in desensitization of somatodendritic 5HT1A auto receptors in the dorsal raphe, and subsequent increase serotonergic transmission in the hippocampus supports the hypothesis that 5HT1A receptors play a role in mood disorders.	Five-HT1A receptor data from numerous research suggest that the 5HT1A receptor has a role in depression and treatment response. Lemonde and colleagues establish a link between the C-1019G 5HT1A promoter polymorphism and serious depression, suicide, and the effectiveness of the antidepressant flibanserin, a 5HT1A agonist.	Chronic lithium therapy in bipolar individuals normalizes abnormalities in 5HT1A receptor binding.
5HT2A receptors	It has been demonstrated that antidepressants decrease the cortex's 5HT2A receptor binding.	Five-HT2A receptor A-1438G, a promoter polymorphism in the 5HTR2A gene, has been linked to serious depression. There have been numerous attempts to find a link between 5HT2A receptor polymorphisms and bipolar disorder, but these studies have not consistently shown any.	Studies examining the binding of the 5HT2A receptor after chronic lithium medication have yielded conflicting findings. Although studies in platelets have shown that lithium-induced increases in 5HT2A receptor binding capacity in bipolar individuals, the majority of research imply that lithium generates a decrease in 5HT2 receptor binding, with the strongest evidence in the hippocampus.